Have a personal or library account? Click to login
Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients Cover

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients

Global Heart
Volume 18 (2023): Issue 1
By: Jialun Han,  Yi Zhang,  Xiujin Shi,  Baidi Lin,  Yunnan Zhang,  Ru Zhang,  Yifan Wang,  Jialin Yan and  Yang Lin  
Open Access
|Mar 2023

References

  1. 1Levine GN, Bates ER, Bittl JA, Brindis RG, Smith SC. ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the. Circulation. 2016; 82(4): E266–E355. DOI: 10.1161/CIR.0000000000000404
    Back to article
  2. 2Marco V, Héctor B, Byrne RA, Jean-Philippe C, Francesco C, Anders J, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal. 2017; 3: e1. DOI: 10.1093/eurheartj/ehx419
    Back to article
  3. 3Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationThe Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2021; 42(14): 1289–367. DOI: 10.1093/eurheartj/ehaa575
    Back to article
  4. 4Han Y. Chinese expert consensus statement on dual antiplatelet therapy in patients with coronary artery disease. Eur Heart J. 2022; 43(13): 1283–5. DOI: 10.1093/eurheartj/ehab741
    Back to article
  5. 5Atherosclerosis, Coronary Heart Disease Working Group of Chinese Society of C, Interventional Cardiology Working Group of Chinese Society of C, Specialty Committee on P, Treatment of Thrombosis of Chinese College of Cardiovascular P, Specialty Committee on Coronary Artery D, et al. Chinese Society of Cardiology and Chinese College of Cardiovascular Physicians Expert Consensus statement on dual antiplatelet therapy in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2021; 49(5): 432–54. DOI: 10.3760/cma.j.cn112148-20210125-00088
    Back to article
  6. 6Agewall S. Antiplatelet treatment in acute coronary syndrome. Still an issue. Eur Heart J Cardiovasc Pharmacother. 2019; 5(3): 125–6. DOI: 10.1093/ehjcvp/pvz018
    Back to article
  7. 7Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, et al. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation. 2020; 142(15): 1425–36. DOI: 10.1161/CIRCULATIONAHA.120.046308
    Back to article
  8. 8Butala NM, Faridi KF, Tamez H, Strom JB, Song Y, Shen C, et al. Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation. 2022; 145(2): 97–106. DOI: 10.1161/CIRCULATIONAHA.121.056878
    Back to article
  9. 9Sim DS, Jeong MH, Kim HS, Gwon HC, Seung KB, Rha SW, et al. Dual antiplatelet therapy beyond 12 months versus for 12 months after drug-eluting stents for acute myocardial infarction. J Cardiol. 2020; 75(1): 66–73. DOI: 10.1016/j.jjcc.2019.06.006
    Back to article
  10. 10Xu J, Song Y, Gao Z, Jiang P, Liu R, Wang H, et al. Long-term outcomes of extending dual antiplatelet therapy after drug-eluting stent implantation for acute coronary syndrome: a large single-center study. Platelets. 2020; 31(7): 869–76. DOI: 10.1080/09537104.2019.1693036
    Back to article
  11. 11Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791–800. DOI: 10.1056/NEJMoa1500857
    Back to article
  12. 12Zheng B, Huo Y, Lee SW, Sawhney JPS, Kim HS, Krittayaphong R, et al. Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study. Clin Cardiol. 2020; 43(9): 999–1008. DOI: 10.1002/clc.23400
    Back to article
  13. 13Zhang Y, Peng W, Shi X, Han J, Wang Y, Fang Z, et al. Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry. Front Cardiovasc Med. 2022; 9: 859962. DOI: 10.3389/fcvm.2022.859962
    Back to article
  14. 14Zhang Y, Shi XJ, Peng WX, Han JL, Lin BD, Zhang R, et al. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. Front Pharmacol. 2020; 11: 582929. DOI: 10.3389/fphar.2020.582929
    Back to article
  15. 15Yin SH, Xu P, Wang B, Lu Y, Wu QY, Zhou ML, et al. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ. 2019; 365: l2222. DOI: 10.1136/bmj.l2222
    Back to article
  16. 16Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23): 2155–66. DOI: 10.1056/NEJMoa1409312
    Back to article
  17. 17Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014; 129(3): 304–12. DOI: 10.1161/CIRCULATIONAHA.113.003303
    Back to article
  18. 18Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012; 125(16): 2015–26. DOI: 10.1161/CIRCULATIONAHA.111.071589
    Back to article
  19. 19Wang W, Wang X, Zhang L, Zhang J, Man F, Pan Q, et al. Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. Front Endocrinol (Lausanne). 2021; 12: 713849. DOI: 10.3389/fendo.2021.713849
    Back to article
  20. 20Zheng YY, Wu TT, Guo QQ, Chen Y, Ma X, Ma YT, et al. Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery disease. Atherosclerosis. 2021; 328: 1–10. DOI: 10.1016/j.atherosclerosis.2021.04.012
    Back to article
  21. 21Wang HY, Dou KF, Wang Y, Yin D, Xu B, Gao RL. Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline. Cardiovasc Drugs Ther. 2020; 34(5): 663–75. DOI: 10.1007/s10557-020-07030-9
    Back to article
  22. 22Wang HY, Dou KF, Yin D, Xu B, Zhang D, Gao RL. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention. Am J Cardiol. 2020; 133: 61–70. DOI: 10.1016/j.amjcard.2020.07.033
    Back to article
  23. 23Costa F, van Klaveren D, Colombo A, Feres F, Raber L, Pilgrim T, et al. A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. Am Heart J. 2020; 223: 44–7. DOI: 10.1016/j.ahj.2020.01.014
    Back to article
  24. 24Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017; 389(10073): 1025–34. DOI: 10.1016/S0140-6736(17)30397-5
    Back to article
  25. 25Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016; 315(16): 1735–49. DOI: 10.1001/jama.2016.3775
    Back to article
  26. 26Gao G, Zhao Y, Zhang D, Song C, Song W, Feng L, et al. Validation of the DAPT score in large-scale consecutive and contemporary patients population in the real world. Platelets. 2021; 32(8): 1084–91. DOI: 10.1080/09537104.2020.1841894
    Back to article
  27. 27Chichareon P, Modolo R, Kawashima H, Takahashi K, Kogame N, Chang CC, et al. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. JACC Cardiovasc Interv. 2020; 13(5): 634–46. DOI: 10.1016/j.jcin.2019.12.018
    Back to article
  28. 28Wester A, Mohammad MA, Olivecrona G, Holmqvist J, Yndigegn T, Koul S. Validation of the 4-Item PRECISE-DAPT Score: A SWEDEHEART Study. J Am Heart Assoc. 2021; 10(20): e020974. DOI: 10.1161/JAHA.121.020974
    Back to article
  29. 29Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–57. DOI: 10.1056/NEJMoa0904327
    Back to article
  30. 30Fricke-Galindo I, Cespedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado A, de Andres F, et al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 2016; 16(2): 113–23. DOI: 10.1038/tpj.2015.70
    Back to article
  31. 31Pereira NL, Rihal C, Lennon R, Marcus G, Shrivastava S, Bell MR, et al. Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. JACC Cardiovasc Interv. 2021; 14(7): 739–50. DOI: 10.1016/j.jcin.2021.01.024
    Back to article
DOI: https://doi.org/10.5334/gh.1185 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Jun 13, 2022
Accepted on: Jan 23, 2023
Published on: Mar 13, 2023
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
acute coronary syndromes,
dual antiplatelet therapy,
percutaneous coronary intervention,
ticagrelor

© 2023 Jialun Han, Yi Zhang, Xiujin Shi, Baidi Lin, Yunnan Zhang, Ru Zhang, Yifan Wang, Jialin Yan, Yang Lin, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 18 (2023): Issue 1Next article